CompletedNCT02050269IoxReaUpdated Dec 22, 2025

Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study

A Phase 3 interventional study of Iohexol in Acute Circulatory Failure, sponsored by University Hospital, Tours. Completed at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by University Hospital, Tours · Phase 3, Interventional, and Diagnostic

Phase: Phase 3
Study type: Interventional
Enrollment: 100
Allocation: Not applicable
Ages: 18 Years and older
Sex: All

Study summary

The objective of this study is to assess the feasibility of estimating the clearance of iohexol as an indirect measure of glomerular filtration rate in patients with unstable renal function in the intensive care unit through analysis of rich iohexol plasma kinetics.

Conditions studied

Acute Circulatory Failure

Browse trials for

Shock 916

In context

Shock

916 studies on the registry are indexed under Shock; 176 are open to participants now.

This study's enrollment of 100 is above the median of 77 across 540 interventional studies indexed under Shock.

Browse Shock studies →

Lead sponsor

University Hospital, Tours is the lead sponsor of 304 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Age ≥ 18 years
Patient admitted to intensive care for less than 12 hours
Acute circulatory failure
Patient carrying an arterial catheter
Informed consent obtained
Affiliated to social security system

Exclusion criteria

Exclusion Criteria:

Administration of iohexol the week before intensive care admission
Administration of iohexol expected within 24 hours of study entry
Known history of cutaneous immediate or delayed allergic reaction to the injection of the product
Indication for albumin transfusion within 24 hours of potential inclusion in the study
Pregnancy or breastfeeding in progress
Patient under guardianship or judicial protection known at the time of inclusion
Withdrawal of consent
Administration of iohexol outside the study within 24 hours after administration of iohexol in the context of the study
Administration of intravenous albumin in the 24 hours following administration of iohexol in the context of the study

Study design

Phase: Phase 3
Primary purpose: Diagnostic
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrollment: 100 participants (actual)

Study arms

Experimental
Iohexol
injection of 5 ml of iohexol
Drug: Iohexol

Interventions

DrugIohexol
Iohexol, 300 mg/mL

What researchers measure

Primary outcomes

Plasma clearance of iohexol
Time frame: 24 hours

Secondary outcomes

Plasma clearance of iohexol in patients developping or not acute kidney injury
Time frame: 7 days
Link between plasma iohexol clearance and kindney injury markers
Time frame: 24 hours
Link between injury and/or functional kidney dammage and subsequent acute kidney injury
Time frame: 7 days
Link between plasma iohexol clearance and urinary metabolomic markers
Time frame: 24 hours
Comparaison of plasma iohexol clearance measured with 3 and 6 vs. 9 kinetic points
Time frame: 24 hours

Study locations

3 sites

Hospital La SOURCE
Orléans, 45000, France
University Hospital Strasbourg
Strasbourg, 67000, France
Service de Réanimation Polyvalente, CHRU de Tours
Tours, 37044, France

References and documents

Publications

Salmon-Gandonniere C, Benz-de Bretagne I, Mercier E, Joret A, Halimi JM, Ehrmann S, Barin-Le Guellec C. Iohexol clearance in unstable critically ill patients: a tool to assess glomerular filtration rate. Clin Chem Lab Med. 2016 Nov 1;54(11):1777-1786. doi: 10.1515/cclm-2015-1202. PubMed 27166722 ↗
Desgrouas M, Merdji H, Bretagnol A, Barin-Le Guellec C, Halimi JM, Ehrmann S, Salmon Gandonniere C. Kinetic Glomerular Filtration Rate Equations in Patients With Shock: Comparison With the Iohexol-Based Gold-Standard Method. Crit Care Med. 2021 Aug 1;49(8):e761-e770. doi: 10.1097/CCM.0000000000004946. PubMed 33710029 ↗

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT02050269
Lead sponsor: University Hospital, Tours
Responsible party: Sponsor
First posted: Jan 30, 2014
Start date: Jan 2014
Primary completion: Jun 2016
Completion: Jun 2016
Last update: Dec 22, 2025

Study contacts

Stephan EHRMANN, MCU-PH

principal investigator · University Hospital, Tours

Oversight

Data monitoring committee: Yes

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Shock→

Other studies from this sponsor

University Hospital, Tours

Start the discussion